ROKIT Healthcare Inc.
Financials
Valuation Metrics
ROKIT Healthcare Inc.'s Market Cap is ₩2953B. At end of 2025 it was ₩1.1T. Ranked #614 of 2,405 in KR market (top 26%), #251 of 1,627 on KOSDAQ (top 15%), #64 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 295.29B KRW | KR#614/2,405 Sec#64/231 |
| Revenue | 32.81B KRW | KR#1,992/2,405 Sec#138/231 |
| Net Income | -12.69B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 108.22B KRW | KR#1,713/2,405 Sec#134/231 |
| Net Assets | 6.72B KRW | KR#2,373/2,405 Sec#227/231 |
| Employees | 86 | KR#1,752/2,405 Sec#140/231 |
| Value | ||
| P/B | 43.93x | KR#2,399/2,405 Sec#231/231 |
| P/S | 9.00x | KR#2,264/2,405 Sec#163/231 |
| FCF Yield | -5.89% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -188.81% | KR#2,362/2,405 Sec#224/231 |
| ROA | -11.73% | KR#2,130/2,405 Sec#162/231 |
| Op. Margin | -46.10% | KR#2,212/2,405 Sec#160/231 |
| Revenue Growth | 106.19% | KR#79/2,405 Sec#15/231 |
| Financial Health | ||
| Debt Ratio | 1509.90% | KR#2,375/2,405 Sec#228/231 |
| Total Debt | 25.05B KRW | KR#1,299/2,405 Sec#102/231 |
| FCF | -17.39B KRW | KR#1,849/2,405 Sec#176/231 |
| Cash | 20.18B KRW | KR#1,249/2,405 Sec#91/231 |
| Current Ratio | 0.89x | KR#1,838/2,405 Sec#178/231 |
| Performance | ||
| 1Y Return | -55.28% | KR#2,102/2,405 Sec#192/231 |
| 1M Return | -39.17% | KR#2,340/2,405 Sec#229/231 |
| From 52W High | -89.02% | KR#2,383/2,405 Sec#227/231 |
| 1Y MDD | -89.20% | KR#2,381/2,405 Sec#226/231 |
| Trading | ||
| Volume | 172,758 shares | KR#427/2,405 Sec#46/231 |
| Trading Value | 2.91B KRW | KR#358/2,405 Sec#32/231 |
| Foreign Own. | 5.72% | KR#762/2,405 Sec#70/231 |
| Per Share | ||
| EPS | -726 KRW | KR—/2,405 Sec—/231 |
| BPS | 384 KRW | KR#2,382/2,405 Sec#227/231 |
Company Info
Rokit Healthcare, established in 2012, leads the innovative regenerative medicine market. The company has commercialized AI ultra-precision patient-specific organ and skin regeneration platforms, built upon four core technologies including AI for medical lesion modeling and disposable regeneration kits. It provides an economical treatment method for chronic diseases, achieving 90% regeneration with a single procedure, and is expanding its application to cartilage and kidney regeneration platforms. Rokit Healthcare is headquartered in Geumcheon-gu, Seoul Metropolitan City.